PMID,Title,Journal,Year
40569464,Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin.,Cancer chemotherapy and pharmacology,2025
38826603,Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes.,Cureus,2024
38530620,Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.,Journal of endocrinological investigation,2024
38416196,Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations.,Naunyn-Schmiedeberg's archives of pharmacology,2024
37556796,Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.,Diabetes care,2023
32704566,The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews.,"Endocrinology, diabetes & metabolism",2020
27689018,The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.,Molecular metabolism,2016
